Blood Pressure Meds In North Carolina Recalled Can ‘Lead To Death’

In a recent announcement, Endo International disclosed that its subsidiary, Par Pharmaceutical (Par), has initiated a voluntary recall of blood pressure medication in North Carolina following concerns about potential health risks associated with the product.

Blood Pressure Medication Recalled in North Carolina Due to Health Risk

The recall was expanded to encompass seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) at the consumer level. Treprostinil Injection, a prostacyclin vasodilator primarily prescribed for the treatment of pulmonary arterial hypertension, is administered via subcutaneous or intravenous infusion. (Seen Below)

Read More: Is It Illegal To Sleep At A North Carolina Rest Area

What Is The Reason For The Recall?

The decision to recall the medication stems from the possible presence of silicone particulates within the product solution. Health officials caution that if these foreign materials enter the bloodstream, they could potentially obstruct blood vessels in critical organs such as the heart, lungs, or brain, leading to severe complications such as stroke or even fatalities.

According to Par Pharmaceutical's statement, the ingestion of an injectable drug contaminated with particulates could result in irritation or swelling at the injection site. The risk escalates if the particles migrate through the bloodstream to other vital organs.

Fortunately, no adverse health incidents related to the contaminated medication have been reported at the time of this writing. However, given the potential risks involved, customers are urged to remain vigilant.

The Affected Products

The recalled products were distributed nationwide to wholesalers and hospitals between June 16, 2022, and August 7, 2023. Concerned individuals who have used or are currently using the affected blood pressure medication are advised to promptly contact their physician or healthcare provider if they experience any unusual symptoms or adverse reactions.

The 7 affected lots are listed below:

• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 57014; Expiration date: 04/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 56911; Expiration date: 04/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 58528; Expiration date: 05/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 58529; Expiration date: 05/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 60064; Expiration date: 07/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 60075; Expiration date: 07/2024
• Treprostinil Injection 20mg/20mL (1mg/mL); NDC: 42023-206-01; Lot #: 67939; Expiration date: 03/2025

Authorities continue to investigate the root cause of the contamination to prevent similar incidents in the future.

Get our free mobile app